Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 9.1 16.8 54.4% View Chart
P/BV x 1.7 1.1 149.6% View Chart
Dividend Yield % 0.6 1.6 39.7%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8303,303 25.1%   
Low Rs5271,797 29.3%   
Sales per share (Unadj.) Rs333.9716.5 46.6%  
Earnings per share (Unadj.) Rs40.479.7 50.6%  
Cash flow per share (Unadj.) Rs51.8107.9 48.0%  
Dividends per share (Unadj.) Rs2.5028.00 8.9%  
Dividend yield (eoy) %0.41.1 33.5%  
Book value per share (Unadj.) Rs237.11,477.5 16.0%  
Shares outstanding (eoy) m585.91184.45 317.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.03.6 57.1%   
Avg P/E ratio x16.832.0 52.6%  
P/CF ratio (eoy) x13.123.6 55.5%  
Price / Book Value ratio x2.91.7 165.9%  
Dividend payout %6.235.1 17.6%   
Avg Mkt Cap Rs m397,569470,292 84.5%   
No. of employees `00017.97.8 228.3%   
Total wages/salary Rs m25,84922,504 114.9%   
Avg. sales/employee Rs Th10,956.916,899.4 64.8%   
Avg. wages/employee Rs Th1,447.72,877.7 50.3%   
Avg. net profit/employee Rs Th1,324.31,879.9 70.4%   
INCOME DATA
Net Sales Rs m195,636132,153 148.0%  
Other income Rs m1,5533,128 49.7%   
Total revenues Rs m197,189135,281 145.8%   
Gross profit Rs m39,51966,290 59.6%  
Depreciation Rs m6,6805,202 128.4%   
Interest Rs m2,62644,097 6.0%   
Profit before tax Rs m31,76720,119 157.9%   
Minority Interest Rs m273,194 0.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2698,611 84.4%   
Profit after tax Rs m23,64514,701 160.8%  
Gross profit margin %20.250.2 40.3%  
Effective tax rate %22.942.8 53.5%   
Net profit margin %12.111.1 108.6%  
BALANCE SHEET DATA
Current assets Rs m153,645122,742 125.2%   
Current liabilities Rs m120,429310,810 38.7%   
Net working cap to sales %17.0-142.3 -11.9%  
Current ratio x1.30.4 323.1%  
Inventory Days Days13523 586.1%  
Debtors Days Days6439 164.0%  
Net fixed assets Rs m103,909116,904 88.9%   
Share capital Rs m586369 158.8%   
"Free" reserves Rs m138,322272,161 50.8%   
Net worth Rs m138,908272,530 51.0%   
Long term debt Rs m1,800270,196 0.7%   
Total assets Rs m264,544856,261 30.9%  
Interest coverage x13.11.5 899.4%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x0.70.2 479.2%   
Return on assets %9.96.9 144.6%  
Return on equity %17.05.4 315.6%  
Return on capital %23.812.4 191.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m97,31615,200 640.2%   
Fx outflow Rs m40,5894,889 830.2%   
Net fx Rs m56,72710,312 550.1%   
CASH FLOW
From Operations Rs m16,220-115,975 -14.0%  
From Investments Rs m-28,768-8,265 348.1%  
From Financial Activity Rs m19,191107,525 17.8%  
Net Cashflow Rs m6,656-16,650 -40.0%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUVEN LIFESCIENCES  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  SHASUN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

RAYMOND Plunges by 5%; BSE 500 Index Up 0.1% (Market Updates)

Nov 14, 2019 | Updated on Nov 14, 2019

RAYMOND share price has plunged by 5% and its current market price is Rs 795. The BSE 500 is up by 0.1%. The top gainers in the BSE 500 Index are SUVEN LIFESCIENCES (up 10.3%) and AEGIS LOGISTICS (up 9.7%). The top losers are RAYMOND (down 5.2%) and AUROBINDO PHARMA (down 9.3%).

GODFREY PHILLIPS Plunges by 6%; BSE 500 Index Up 0.1% (Market Updates)

Nov 14, 2019 | Updated on Nov 14, 2019

GODFREY PHILLIPS share price has plunged by 6% and its current market price is Rs 1,329. The BSE 500 is up by 0.1%. The top gainers in the BSE 500 Index are AEGIS LOGISTICS (up 10.9%) and SUVEN LIFESCIENCES (up 8.1%). The top losers are GODFREY PHILLIPS (down 6.4%) and AUROBINDO PHARMA (down 8.6%).

DEEPAK FERTILISERS Plunges by 5%; BSE 500 Index Down 0.1% (Market Updates)

Nov 14, 2019 | Updated on Nov 14, 2019

DEEPAK FERTILISERS share price has plunged by 5% and its current market price is Rs 99. The BSE 500 is down by 0.1%. The top gainers in the BSE 500 Index are AEGIS LOGISTICS (up 6.4%) and MOTILAL OSWAL (up 5.0%). The top losers are DEEPAK FERTILISERS (down 5.0%) and AUROBINDO PHARMA (down 8.5%).

NARAYANA HRUDAYALAYA LTD Plunges by 6%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Nov 14, 2019 | Updated on Nov 14, 2019

NARAYANA HRUDAYALAYA LTD share price has plunged by 6% and its current market price is Rs 308. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index are CADILA HEALTHCARE (up 4.3%) and DR. LAL PATHLABS LTD (up 4.0%). The top losers are NARAYANA HRUDAYALAYA LTD (down 5.5%) and AUROBINDO PHARMA (down 8.4%).

MAGMA FINCORP Plunges by 5%; BSE 500 Index Up 0.3% (Market Updates)

Nov 14, 2019 | Updated on Nov 14, 2019

MAGMA FINCORP share price has plunged by 5% and its current market price is Rs 46. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are AEGIS LOGISTICS (up 6.1%) and DR. LAL PATHLABS LTD (up 5.1%). The top losers are MAGMA FINCORP (down 5.3%) and AUROBINDO PHARMA (down 8.2%).

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 14, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS